Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1

Babafemi Taiwo*, Charles Hicks, Joseph Eron

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Significant advances in outcomes have been achieved with combination antiretroviral therapy (cART) in patients living with HIV. However, several ongoing needs remain with respect to the development of new treatments. The need for new or enhanced cART may become increasingly apparent as patients live longer with HIV and a greater proportion die from non-AIDS-related illnesses. Immunological response to cART is variable and immune failure occurs, despite virological control. Moreover, viral suppression can be incomplete due to insufficient antiviral efficacy, acquired or transmitted drug resistance, suboptimal pharmacokinetics/pharmacodynamics and lack of adherence. Chronic immune activation may continue even when viral replication is relatively restrained. Patients continue to experience cardiovascular and metabolic complications, due to disease, treatment and ageing. In addition, neurocognitive impairment and malignancy are important sources of ongoing morbidity despite cART. HIV also affects immune system senescence and bone turnover. This review discusses potential unmet needs with respect to these issues.

Original languageEnglish (US)
Article numberdkq096
Pages (from-to)1100-1107
Number of pages8
JournalJournal of Antimicrobial Chemotherapy
Issue number6
StatePublished - Mar 25 2010


  • Co-morbidities
  • HIV
  • Needs
  • Persistence
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1'. Together they form a unique fingerprint.

Cite this